Skip to main content

Table 3 Studies on endothelial function by arterial tonometry or vasodilation in response to pharmacological stimuli in migraineurs

From: Peripheral vascular dysfunction in migraine: a review

Study (First author, year)

Study design

Patients included (n)

% women

Exclusion criteria

Migraine diagnosis

Results

Arterial tonometry

      

Jiménez-Caballero, 2013 [31]

CC

CM: 21

71

Age ≥50, CVD, inflammatory disease, obesity, HYP, DM, dyslipidemia, CS, active cancer, ovarium pathology, pregnancy or lactation, regular use of vasoactive drugs

ICHD-II

Smaller RHI in migraineurs

Controls: 21

Liman, 2012 [32]

CC

MwA: 29

100

CVD, obesity, HYP, DM, pregnancy, use of drugs (statins, anticoagulants or antiplatelet and intake of triptans within the previous 24 h)

ICHD-II

No differences in PAT ratio between migraineurs and controls

Controls: 30

Vasodilation in response to pharmacological stimuli

De Hoon, 2006 [20]

CC

Migraine: 10

60

CVD, HYP, DM, dyslipidemia, CS

ICHD-I

No differences between migraineurs and controls in vasodilation response to serotonin, sodium nitroprusside, and CGRP

Controls: 10

Edvinsson, 2008 [33]

CC

MwoA: 9

78

None

ICHD-I

No differences between migraineurs and controls in vasodilation response after local heating and iontophoretic administration of acetylcholine, sodium nitroprusside, and CGRP

Controls: 9

Napoli, 2009 [34]

CC

MwoA: 12

58

HYP, DM, hypercholesterolemia, CVD, CS

ICHD-I

Reduced response to endothelium-dependent vasodilation and production of cGMP in migraineurs; no difference in production of NO

Controls: 12

Vanmolkot, 2010 [35]

CC

Migraine:16

75

Age >50, CVD, HYP, obesity, DM, CS, dyslipidemia, pregnancy or lactation, use of vasoactive drugs (except OC)

ICHD-II

No differences between migraineurs and controls to sodium nitroprusside, substance P, and NG-monomethyl-L-arginine

Controls: 16

Yetkin, 2007 [30]

CC

Migraine: 24

89

HYP, CAD, DM, infectious disease

ICHD-I

Higher nitrate-mediated dilation in migraineurs

  

Controls: 26

    
  1. CC case–control; CM chronic migraine; MwA migraine with aura; MwoA migraine without aura; CVD cardiovascular disease; HYP arterial hypertension; DM,diabtes mellitus; CS cigarette smoking; OC oral contraceptive; ICHD International classification headache disorders; RHI reactive hyperhemia index; PAT peripheral arterial tonometry; CGRP Calcitonin Gene Related Peptide; cGMP cyclic guanosine monophosphate; NO nitric oxide.